R
Romulus Capital Management, LLC
+ HoldingHIND
+0.00%
3M Return
$2.205
-0.005 (-0.23%)Al cierre
Loading chart…
- High
- 2.265
- Open
- 2.265
- VWAP
- 2.23
- Vol
- 2.29K
- Mkt Cap
- —
- Low
- 2.205
- Amount
- 5.09K
- EV/EBITDA, TTM
- -0.96
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
AI analysis of Vyome Holdings Inc (HIND)
buyVyome Holdings Inc is a good buy right now due to its recent revenue performance and analyst optimism. The company reported a Q1 revenue of $31.59 million, showing stable growth despite challenges, and has a significant analyst price target of $8, indicating a potential upside of over 260% from the current price of $2.21. However, the main risk lies in the company's net loss of approximately $963,000 for Q1 2026, which highlights ongoing financial pressures.
Métricas de valoración
The current forward P/E ratio for Vyome Holdings Inc (HIND) is 0.00, compared to its 5-year average forward P/E of -8.15.
Whales holding HIND
Cronología de eventos
Noticias
9.505-29seekingalphaVyome Holdings Reports Q1 Revenue of $31.59M
7.505-28NewsfilterVyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- 9.503-26seekingalpha
Vyome Holdings Reports FY 2025 Financial Results
- 8.502-18Newsfilter
Vyome Publishes Preclinical Data for VT-1908
8.012-31BusinesswireHarvest Announces 2025 ETF Reinvested Distributions
HIND FAQ — answered by Alphio AI
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology. It operates in the Healthcare sector.
Vyome Holdings Inc is a good buy right now due to its recent revenue performance and analyst optimism. The company reported a Q1 revenue of $31.59 million, showing stable growth despite challenges, and has a significant analyst price target of $8, indicating a potential upside of over 260% from the current price of $2.21. However, the main risk lies in the company's net loss of approximately $963,000 for Q1 2026, which highlights ongoing financial pressures.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.